Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option

被引：18
作者：
Mayor, Nikhil [1 ]
Sathianathen, Niranjan J. [1 ]
Buteau, James [2 ]
Koschel, Samantha [1 ]
Juanilla, Marta Anton [1 ]
Kapoor, Jada [1 ]
Azad, Arun [3 ,4 ]
Hofman, Michael S. [2 ,4 ]
Murphy, Declan G. [1 ,4 ]
机构：
[1] Peter MacCallum Canc Ctr, Div Canc Surg, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Mol Imaging & Nucl Med Therapeut, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[4] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
来源：
BJU INTERNATIONAL | 2020年 / 126卷 / 05期
关键词：
prostate cancer; prostate-specific membrane antigen; theranostics; lutetium; metastatic; castration resistant; neoadjuvant; #PCSM; #ProstateCancer; POSITRON-EMISSION-TOMOGRAPHY; DIAGNOSTIC-ACCURACY; MONOCLONAL-ANTIBODY; BONE-SCINTIGRAPHY; FOLATE HYDROLASE; PSMA-LIGAND; PET; EXPRESSION; RECURRENCE; F-18-PSMA-1007;
D O I：
10.1111/bju.15143
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Objectives To review current data for the role of prostate specific membrane antigen (PSMA) radioligand therapy (RLT) for patients with advanced prostate cancer. This review provides an update for multidisciplinary teams on the current and potential future applications of theranostics in prostate cancer. Methods Narrative review focussing on PSMA as a target for RLT, and data using Results RLT with PSMA is an exciting therapeutic alternative to the existing management options already in use for patients with metastatic castrate-resistant prostate cancer (mCRPC). To date, most evidence exists regarding small-molecule PSMA inhibitors bound to beta-emitting radioisotopes such as 177Lu (Lu-PSMA). Prospective phase II data supports the safety and efficacy of Lu-PSMA in men with heavily pre-treated progressive mCRPC, and several late-phase randomised trials of Lu-PSMA are underway, with many more in the pipeline. Early results are encouraging, indicating that the theranostic approach may play a vital role in management of advanced prostate cancer and perhaps even in much earlier disease states. Conclusions PSMA RLT is a promising new treatment option for men with mCPRC, and may also have utility in less advanced prostate cancer.
引用
收藏
页码：525 / 535
页数：11
相关论文
共 76 条
[21]   68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals [J].
Fani, Melpomeni ;
Andre, Joao P. ;
Maecke, Helmut R. .
CONTRAST MEDIA & MOLECULAR IMAGING, 2008, 3 (02) :53-63
[22]   Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments [J].
Farolfi, Andrea ;
Fendler, Wolfgang ;
Iravani, Amir ;
Haberkorn, Uwe ;
Hicks, Rodney ;
Herrmann, Ken ;
Walz, Jochen ;
Fanti, Stefano .
EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (02) :152-162
[23]   Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617 [J].
Ferdinandus, Justin ;
Violet, John ;
Sandhu, Shahneen ;
Hicks, Rodney J. ;
Ravi Kumar, Aravind S. ;
Iravani, Amir ;
Kong, Grace ;
Akhurst, Tim ;
Thang, Sue Ping ;
Murphy, Declan G. ;
Williams, Scott ;
Hofman, Michael S. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (10) :2322-2327
[24]   EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy [J].
Giammarile, Francesco ;
Chiti, Arturo ;
Lassmann, Michael ;
Brans, Boudewijn ;
Flux, Glenn .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (05) :1039-1047
[25]   Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study [J].
Giesel, Frederik L. ;
Will, Leon ;
Lawal, Ismaheel ;
Lengana, Thabo ;
Kratochwil, Clemens ;
Vorster, Mariza ;
Neels, Oliver ;
Reyneke, Florette ;
Haberkon, Uwe ;
Kopka, Klaus ;
Sathekge, Mike .
JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (07) :1076-1080
[26]   Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 [J].
Gillessen, S. ;
Omlin, A. ;
Attard, G. ;
de Bono, J. S. ;
Efstathiou, E. ;
Fizazi, K. ;
Halabi, S. ;
Nelson, P. S. ;
Sartor, O. ;
Smith, M. R. ;
Soule, H. R. ;
Akaza, H. ;
Beer, T. M. ;
Beltran, H. ;
Chinnaiyan, A. M. ;
Daugaard, G. ;
Davis, I. D. ;
De Santis, M. ;
Drake, C. G. ;
Eeles, R. A. ;
Fanti, S. ;
Gleave, M. E. ;
Heidenreich, A. ;
Hussain, M. ;
James, N. D. ;
Lecouvet, F. E. ;
Logothetis, C. J. ;
Mastris, K. ;
Nilsson, S. ;
Oh, W. K. ;
Olmos, D. ;
Padhani, A. R. ;
Parker, C. ;
Rubin, M. A. ;
Schalken, J. A. ;
Scher, H. I. ;
Sella, A. ;
Shore, N. D. ;
Small, E. J. ;
Sternberg, C. N. ;
Suzuki, H. ;
Sweeney, C. J. ;
Tannock, I. F. ;
Tombal, B. .
ANNALS OF ONCOLOGY, 2015, 26 (08) :1589-1604
[27]   Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? [J].
Gomez, P ;
Manoharan, M ;
Kim, SS ;
Soloway, MS .
BJU INTERNATIONAL, 2004, 94 (03) :299-302
[28]   Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis [J].
Han, Sangwon ;
Woo, Sungmin ;
Kim, Yeon Joo ;
Suh, Chong Hyun .
EUROPEAN UROLOGY, 2018, 74 (02) :179-190
[29]   Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer [J].
Heck, Matthias M. ;
Tauber, Robert ;
Schwaiger, Sebastian ;
Retz, Margitta ;
D'Alessandria, Calogero ;
Maurer, Tobias ;
Gafita, Andrei ;
Wester, Hans-Juergen ;
Gschwend, Juergen E. ;
Weber, Wolfgang A. ;
Schwaiger, Markus ;
Knorr, Karina ;
Eiber, Matthias .
EUROPEAN UROLOGY, 2019, 75 (06) :920-926
[30]   RADIOACTIVE IODINE IN THE STUDY OF THYROID PHYSIOLOGY .7. THE USE OF RADIOACTIVE IODINE THERAPY IN HYPERTHYROIDISM [J].
HERTZ, S ;
ROBERTS, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1946, 131 (02) :81-86
12345678